• Opus Genetics' third-quarter 2026 net loss more than doubled year over year to $46.5 million.
• License and collaborations revenue fell 63% year over year to $1.14 million, while research and development expenses more than doubled to $14.49 million.
• Cash and cash equivalents totaled $89 million at September 30; resources including potential Oberland funding are expected to support operations into 2029.
• OPGx-BEST1 high-dose cohort dosing is complete, with topline data expected in Q1 2027.
• The fully enrolled OPGx-LCA5 registrational Phase 3 trial is expected to begin dosing in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873270) on November 10, 2026, and is solely responsible for the information contained therein.